Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 28,000 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 28,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the completion of the transaction, the chief financial officer owned 129,855 shares of the company’s stock, valued at $3,746,316.75. This trade represents a 17.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.42, for a total value of $187,864.00.
• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.00, for a total value of $211,600.00.

Bicara Therapeutics Stock Down 2.6%

Shares of BCAX stock traded down $0.77 during trading on Friday, reaching $28.91. The company’s stock had a trading volume of 584,437 shares, compared to its average volume of 1,011,479. Bicara Therapeutics Inc. has a one year low of $9.47 and a one year high of $30.99. The business has a fifty day moving average price of $23.43 and a 200-day moving average price of $20.10. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -10.40 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Research analysts anticipate that Bicara Therapeutics Inc. will post -3.48 EPS for the current year.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its stake in Bicara Therapeutics by 0.9% in the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after purchasing an additional 1,171 shares during the period. Legal & General Group Plc grew its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Mariner LLC increased its position in Bicara Therapeutics by 3.0% during the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after acquiring an additional 1,902 shares during the period. Invesco Ltd. boosted its holdings in Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares during the period. Finally, Quantinno Capital Management LP grew its position in shares of Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after purchasing an additional 2,447 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BCAX. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday. HC Wainwright raised their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Morgan Stanley boosted their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.